ALDX
Legal baggage, now in a bigger suitcase
Aldeyra Therapeutics is back in the spotlight, and not for the reasons management probably wanted. A securities fraud class action was filed on behalf of investors who bought ALDX shares between November 3, 2023 and March 16, 2026, accusing the company of not fully disclosing that reproxalap’s clinical trial results were inconsistent.
The FDA door slam didn’t help
The lawsuit leans hard on the March 17 SEC filing, when Aldeyra said it had received a Complete Response Letter from the FDA for reproxalap in dry eye disease. The agency’s message was basically: the evidence wasn’t strong enough, the study results looked shaky, and the total package didn’t prove the drug worked the way Aldeyra had hoped.
Why investors should care
That’s not just legal noise. When a biotech’s lead asset gets rejected and shareholders claim the company oversold the data, you can end up with a double hit: regulatory risk on one side, litigation risk on the other. ALDX already plunged after the FDA news, and this lawsuit keeps the pressure on.
Big picture
For small-cap biotech, confidence is currency. When that currency gets questioned by both regulators and plaintiffs’ lawyers, the market usually doesn’t hand out second chances for free.